度洛西汀联合普拉克索对帕金森病伴抑郁患者的疗效及安全性分析

Efficacy and safety of duloxetine combined with pramipexole in Parkinson's disease patients with depression

目的探讨度洛西汀联合普拉克索片治疗帕金森病伴抑郁患者的临床疗效,并分析用药安全性。方法选取新乡医学院第一附属医院门诊及住院的90例原发性帕金森病伴抑郁患者,按照随机数字表法分为试验组和对照组,试验组给予度洛西汀联合普拉克索治疗,对照组仅给予普拉克索治疗。分别在治疗前及治疗8周后评估两组患者统一帕金森病评分量表(UPDRS)汉密尔顿抑郁量表-24(HAMD-24)及汉密尔顿焦虑量表(HAMA)评分,比较两组患者的治疗效果及副作用。结果治疗前,两组患者UPDRS、HAMD、HAMA量表评分差异均无统计学意义(P>0.05)。治疗后两组患者上述评分与治疗前相比均明显降低(P<0.05),试验组患者UPDRS、HAMD、HAMA量表评分明显低于对照组(P<0.05)。两组患者副反应间差异无统计学意义(P>0.05)。结论度洛西汀联合普拉克索能更好地改善帕金森伴抑郁患者的抑郁焦虑症状、提高患者的生活质量,且不会增加治疗的并发症及副作用。

Objective To explore the clinical efficacy of duloxetine combined with pramipexole in the treatment of patients with Parkinson's disease and depression,and analyze the safety of the medication.Methods A total of 90 patients with primary Parkinson's disease and depression in the first affiliated hospital of Xinxiang Medical College were selected and divided into experimental group and control group according to the random number table.Before and after 8 weeks of treatment,the scores of UPDRS and HAMD and HAMA,and side effects after treatment between two groups were compared.Results Before treatment,there was no statistically significant difference in UPDRS,HAMD,and HAMA scale scores between the two groups(P>0.05).After treatment,the scores of UPDRS,HAMD,and HAMA scale in both the two groups were significantly lower than those before treatment(P<0.05).The scores of UPDRS,HAMD,and HAMA scales in the experimental group were lower than those in the control group(P<0.05)after treatment.There was no significant difference in side effects between the two groups(P>0.05).Conclusion Duloxetine combined with pramipexole is effective and safe in the treatment of Parkinson's patients disease with depression.